Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304362 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Hye Jung Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Muscarinic Antagonists, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Drug Safety.
Themen: COPD
Abstract (Originalsprache)
This study aimed to define real-world prescription patterns in Korea and compare the effectiveness of chronic obstructive pulmonary disease (COPD) medications. We used national claims data provided by the Health Insurance Review and Assessment Service in Korea and examined patients who were first diagnosed with COPD and started treatment between May 1, 2017, and April 30, 2018, with no change in drug regimen. Among 30,784 patients with COPD, long-acting β 2 agonist (LABA) combined with long-acting muscarinic antagonist (LAMA) (32.7%), inhaled corticosteroid-LABA (ICS–LABA) (25.6%), LAMA (18.3%), ICS (5.8%), or LABA (4.6%) were prescribed as the first-choice inhalers. The use of LABA–LAMA (hazard ratio [HR], 0.248–0.584), LAMA (HR, 0.320–0.641), ICS–LABA (HR, 0.325–0.643), and xanthine (HR, 0.563–0.828) significantly reduced the total and severe exacerbation rates compared with no use of each medication. However, the use of ICS or LABA individually did not yield such effects. The continued use of LABA–LAMA, LAMA, and ICS–LABA showed a significant effect on exacerbation rate, whereas the long-term use of ICS, LABA, and xanthine did not. Moreover, some high doses of ICS–LABA did not show significant effects. This real-world study revealed that LAMA and/or LABA could be the first choice of therapy, as recommended by recent guidelines. However, ICS, xanthine, and high-dose ICS–LABA are still being prescribed frequently as first-line drugs in Korea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Healthcare Insurance Review & Assessment Service, Wonju, Republic of Korea.
- Division of Allergy and Immunology, Department of Internal Medicine, Republic of Korea.
- Institute of Allergy, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Hye Jung Park, Soyoung Jeon, Hye Sun Lee, Jae-Hyun Lee
Förderung
- Ministry of Food and Drug Safety
Zitieren
APA
Park, H. J., Lee, J. U., Jeon, S., Lee, H. S., Kim, B. Y., Chae, Y. J., Kim, G. O., Park, J. W., & Lee, J. H. (2024). Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings. PLOS ONE. https://doi.org/10.1371/journal.pone.0304362
Vancouver
Park HJ, Lee JU, Jeon S, Lee HS, Kim BY, Chae YJ, et al. Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings. PLOS ONE. 2024. doi:10.1371/journal.pone.0304362
BibTeX
@article{Park2024,
author = {Park, Hye Jung and Lee, Jae Uk and Jeon, Soyoung and Lee, Hye Sun and Kim, Bo Yeon and Chae, Yu Jin and Kim, Gui Ok and Park, Jung-Won and Lee, Jae-Hyun},
title = {Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304362}
}
EUVIMED